Issued Patents All Time
Showing 1–21 of 21 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 12130295 | NMR system and methods for multi-parameter metabolic vulnerability index evaluations | James D. Otvos | 2024-10-29 |
| 11988679 | Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter | James D. Otvos | 2024-05-21 |
| 11990243 | Multiple-marker risk parameters predictive of conversion to diabetes | James D. Otvos | 2024-05-21 |
| 11710568 | Multi-parameter diabetes risk evaluations | James D. Otvos, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier | 2023-07-25 |
| 11703501 | CHD risk stratification evaluations for subjects with high levels of large HDL-P | James D. Otvos | 2023-07-18 |
| 11692995 | NMR measurements of NMR biomarker GlycA | James D. Otvos, Dennis W. Bennett, Justyna E. Wolak-Dinsmore | 2023-07-04 |
| 11467171 | Methods and systems to detect and quantify the amount of LP-X and other abnormal lipoproteins in a biosample using NMR spectroscopy | James D. Otvos, Alan T. Remaley, Maureen Sampson, Lita Freeman | 2022-10-11 |
| 11231429 | Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter | James D. Otvos | 2022-01-25 |
| 11156621 | Multi-parameter metabolic vulnerability index evaluations | James D. Otvos | 2021-10-26 |
| 11037683 | Multiple-marker risk parameters predictive of conversion to diabetes | James D. Otvos | 2021-06-15 |
| 10852293 | NMR measurements of NMR biomarker GlycA | James D. Otvos, Dennis W. Bennett, Justyna E. Wolak-Dinsmore | 2020-12-01 |
| 10386355 | CHD risk stratification evaluations for subjects with high levels of large HDL-P | James D. Otvos | 2019-08-20 |
| 10388414 | Multi-parameter diabetes risk evaluations | James D. Otvos, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier | 2019-08-20 |
| 9952232 | Cardiovascular risk evaluations using a risk parameter that includes an HDL and inflammatory biomarker interaction parameter | James D. Otvos | 2018-04-24 |
| 9928345 | Multiple-marker risk parameters predictive of conversion to diabetes | James D. Otvos | 2018-03-27 |
| 9792410 | Multi-parameter diabetes risk evaluations | James D. Otvos, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier | 2017-10-17 |
| 9483611 | Protective HDL particle number evaluations | James D. Otvos | 2016-11-01 |
| 9483612 | CHD risk stratification evaluations for subjects with high levels of large HDL-P | James D. Otvos | 2016-11-01 |
| 9470771 | NMR measurements of NMR biomarker GlycA | James D. Otvos, Dennis W. Bennett, Justyna E. Wolak-Dinsmore | 2016-10-18 |
| 9361429 | Multi-parameter diabetes risk evaluations | James D. Otvos, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier | 2016-06-07 |
| 6617167 | Method of determining presence and concentration of lipoprotein X in blood plasma and serum | James D. Otvos, Elias J. Jeyarajah | 2003-09-09 |